On August 8, we announced that we had obtained a patent on functionalised derivatives of sodium saccharin and how they are manufactured.
This patent was filed through a joint study with Professors Suhng Wook Kim and Un chul Shin of Korea University’s School of Health and Environmental Science. This work was also reported in an article published on October 29 in the International Journal of Labelled Compounds and Radiopharmaceuticals. The title of the article is “Development of a 68Ga‐labelled PET tracer for carbonic anhydrase IX‐overexpressed tumors using the artificial sweetener saccharin”.
The patent concerns sodium saccharin and manufacturing methods of its derivatives combined with a ligand compound having an optional targeting action for hypoxic tumors. Sulfonamide-based substances, such as saccharin, show selective binding to Carbonic Anhydrase IX (CA IX) that occurs in tumor cells. Saccharin derivatives can therefore be used to safely and effectively diagnose cancerous tumor cells.
The results of this study confirmed the potential for saccharin derivatives to be used as new diagnostic pharmaceutical agents in addition to existing uses in various medicines, food ingredients, beverages, toothpastes, etc. as artificial sweeteners. We plan to continue joint research with domestic researchers to ensure that saccharin is commercially available as a building block for diagnostic substances in tumor cells.
For related articles, see the links below.
“Catch cancer with saccharin….What are KISCO’s Patents?” – Money Today Broadcasting (mtn.co.kr)
“Development of a 68Ga‐labelled PET tracer for carbonic anhydrase IX‐overexpressed tumors using the artificial sweetener saccharin” – International Journal of Labelled Compounds and Radiopharmaceuticals
